Relentless dedication to serving patients with serious rare and ultra-rare genetic diseases
At Ultragenyx, we have a unique formula for drug development that reflects our shared urgency to accelerate the timelines for delivering safe and effective new medicines to patients. We do this by taking a deliberate approach in three areas:
We build our commercial models with access to drug as a priority. This means that we price responsibly, launch globally, and have developed an industry-leading UltraCare program to support patients in navigating access to treatments. We are also committed to helping the rare disease community move forward by sharing our science and expertise to advance future development.
View the UltraCare Program
Our team is comprised of exceptional and diverse talent with a strong passion and commitment to helping patients. We encourage generosity, curiosity, and humility so that we are constantly learning together, fostering an environment that supports profound growth and fulfillment.
Learn more about our team culture
Using a dynamic development model that engages patients at every stage from discovery to translational research to clinical development, we are able to learn and adapt rapidly. This model has helped us to successfully move our programs through the clinic to approval at an average pace of 5.5 years, compared to the industry average of (at least) 7.5 years.
Explore our pipeline
Our success to date is driven by our productive partnerships with academia and industry.
We are interested in hearing from people who, like us, are focused on improving the lives of people living with serious rare and ultra-rare genetic diseases.
Want to get in touch? Contact us